There are currently 1308 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: The Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
NCT04278118
Recruiting
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm, Nerve Sheath Neoplasm, Pituitary Gland Adenoma, Schwannoma
Register for Updates
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
NCT02602262
Recruiting
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected (HIV-) donors will also be followed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Emory University, Atlanta, Georgia
Conditions: HIV Infection
Register for Updates
Oral Anti Diabetic Agents in the Hospital
NCT04416269
Recruiting
This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in the management of diabetes in the hospital. The primary outcome of the study is to determine differences in glycemic control as measured by mean daily blood glucose concentration between oral antidiabetic medications and basal bolus therapy in hospitalized patients with type 2 diabetes (T2D).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/09/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Diabetes Mellitus
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Emory University - Winship Cancer Institute, Atlanta, Georgia
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
NCT05488145
Recruiting
This clinical trial looks at the use of an internet-based application (app) intervention in improving adherence to endocrine therapy (ET) among patients with early stage hormone receptor-positive HER2-negative breast cancer. ET can significantly reduce the return of the cancer in patients who are compliant with their treatment regimen. Despite this, adherence to ET is poor due to side effects, lack of social support and timely access to clinicians, and poor patient understanding of the necessity... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia +2 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065
Recruiting
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response c... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
12/06/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Spinal Cord Glioma, Recurrent Malignant Central Nervous System Neoplasm, CNS Tumor, Central Nervous System Tumor, World Health Organization (WHO) Grade III Glioma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia
Conditions: Solid Tumor
Register for Updates
Prostate Active Surveillance Study
NCT00756665
Recruiting
The Prostate Active Surveillance Study (PASS) is a research study for men who have chosen active surveillance as a management plan for their prostate cancer. Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results. This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly.
Gender:
MALE
Ages:
21 years and above
Trial Updated:
12/06/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Prostatic Neoplasms
Register for Updates
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
NCT06238778
Recruiting
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/05/2024
Locations: Atlanta Diabetes Associates, Atlanta, Georgia
Conditions: Diabetes Mellitus, Type 1
Register for Updates
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
NCT04656496
Recruiting
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over time. With over 80% of pediatric cancer patients living to adulthood, many pediatric cancer survivors experience long-term health consequences such as heart disease - the leading cause of death in this population. The purpose of this clinical research study is to teach parents/caregivers skills that will help prevent and reduce the problems... Read More
Gender:
ALL
Ages:
Between 5 years and 14 years
Trial Updated:
12/05/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Obesity, Childhood, Cancer, Survivorship
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates